Literature DB >> 3293975

Cefotaxime treatment of gram-negative enteric meningitis in infants and children.

R F Jacobs1.   

Abstract

18 infants and children (1 week to 3 months of age) were treated with cefotaxime 200 mg/kg/day for Gram-negative enteric bacillary meningitis. 17 of these patients (94.4%) survived, with a complication rate of 23.5% (4/17 patients). The follow-up cerebrospinal fluid cultures at 24 hours were sterile in all patients. Cefotaxime was safe and effective in treating Gram-negative enteric bacillary meningitis in infants and children and should be considered as a potential drug of choice in Gram-negative neonatal meningitis due to susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293975     DOI: 10.2165/00003495-198800352-00039

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  20 in total

1.  Changes in the pattern of neonatal septicemia and meningitis.

Authors:  G H McCracken; H R Shinefield
Journal:  Am J Dis Child       Date:  1966-07

2.  Intraventricular use of aminoglycosides in the treatment of gram-negative bacillary meningitis: conflicting views.

Authors:  M N Swartz
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

3.  A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.

Authors:  G H McCracken; S G Mize
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

4.  Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation.

Authors:  G H McCracken; N Threlkeld; S Mize; C J Baker; S L Kaplan; I Faingezicht; W E Feldman; U Schaad
Journal:  JAMA       Date:  1984-09-21       Impact factor: 56.272

5.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

6.  Cefotaxime therapy of neonatal gram-negative bacillary meningitis.

Authors:  S H Naqvi; M A Maxwell; L M Dunkle
Journal:  Pediatr Infect Dis       Date:  1985 Sep-Oct

7.  A prospective randomized comparison of cefotaxime vs ampicillin and chloramphenicol for bacterial meningitis in children.

Authors:  R F Jacobs; T G Wells; R W Steele; T Yamauchi
Journal:  J Pediatr       Date:  1985-07       Impact factor: 4.406

8.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

9.  Pharmacokinetics of cefotaxime in neonates.

Authors:  J Baird-Lambert; P E Doyle; D Thomas; M Cvejic; N Buchanan
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

10.  Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.

Authors:  E L Francke; H C Neu
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

View more
  6 in total

1.  The Advantage of Bactericidal Drugs in the Treatment of Infection.

Authors:  Jeffrey Alder; Barry Eisenstein
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

Review 2.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

3.  Transient in vivo selection of a constitutively cephalosporin resistant Enterobacter cloacae causing ventriculitis.

Authors:  A Joffe; A Kabani; K Ramotar; W Krulicki; G Cadrain; T Jadavji
Journal:  Can J Infect Dis       Date:  1995-01

Review 4.  Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.

Authors:  G L Kearns; R A Young; R F Jacobs
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 5.  Efficacy and safety of cefotaxime in the management of pediatric infections.

Authors:  R F Jacobs
Journal:  Infection       Date:  1991       Impact factor: 3.553

6.  Cefotaxime pharmacokinetics and treatment of meningitis in neonates.

Authors:  R F Jacobs; G L Kearns
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.